JOURNAL OF NEW CENTURY INNOVATIONS
Volume–76_Issue-1_May-2025
562
562
562
562
HISTOLOGICAL AND NEUROENDOCRINE MECHANISMS
OF PREMENSTRUAL SYNDROME: A CLINICAL AND
MICROSCOPIC PERSPECTIVE
Abdumannopova Nigora Sobirjon qizi
Student of the Faculty of Second Medical Treatment,
Tashkent Medical Academy. Phone: 99 478 68 07
Scientific Advisor:
Tursunmetov Ibodulla
Department of Medical Biology and Histology,
Tashkent Medical Academy
Abstract:
Premenstrual syndrome (PMS) affects a majority of women during
their reproductive years, with symptoms that extend beyond mood swings to include
histologically rooted changes. This article explores the interplay between hormonal
fluctuations and tissue-level responses in the brain and reproductive system. Using both
personal observations and academic literature, the study identifies how estrogen,
progesterone, and neurotransmitters like serotonin contribute to PMS. Through this
dual analysis, we highlight the biological basis of symptoms often dismissed as minor.
Diagrams and tables are included to aid in visualizing these complex mechanisms. This
paper aims to provide both scientific insight and practical understanding of PMS.
Key words:
Premenstrual syndrome (PMS), Hormonal fluctuations, Estrogen,
Progesterone, Histological changes, Neuroendocrine mechanisms, Menstrual cycle,
GABA receptors, Serotonin, Endometrial inflammation.
Introduction
Premenstrual syndrome (PMS) is a multifactorial condition that arises in the luteal
phase of the menstrual cycle, usually 5–10 days before menstruation. Characterized by
a range of physical, emotional, and cognitive symptoms, PMS is experienced by up to
85% of reproductive-aged women. Symptoms such as breast tenderness, nausea,
irritability, anxiety, and sleep disturbances are often regarded as routine, but in reality,
they are the result of complex neuroendocrine and histological interactions.
The fluctuations in estrogen and progesterone levels affect not only mood and
behavior but also tissue-level changes in the endometrium, hypothalamus, and limbic
system. Despite its prevalence, the biological basis of PMS remains poorly understood
by the general public. This paper investigates the neuroendocrine feedback loops and
histological changes that occur during PMS, providing an in-depth yet accessible
explanation of a familiar phenomenon.
JOURNAL OF NEW CENTURY INNOVATIONS
Volume–76_Issue-1_May-2025
563
563
563
563
Methods
This study combines personal observation with scientific research. A small
informal survey and individual interviews were conducted among 20 female medical
students aged 18–24. Participants were asked to report symptoms experienced during
the premenstrual phase. Commonly reported issues included mood instability, food
cravings, bloating, fatigue, and increased sensitivity.
To complement the observational data, a literature review was performed using
PubMed, ScienceDirect, and Google Scholar. Search terms included “PMS,”
“histological changes in PMS,” “neuroendocrine mechanisms,” and “estrogen
progesterone brain effect.” Articles published between 2013 and 2023 were selected to
ensure recent data. Key focus areas included brain tissue response to hormone shifts,
neurotransmitter involvement, and immune cell activity in uterine and CNS tissues.
Results
The informal survey revealed the most common PMS symptoms among
participants as follows:
Figure 1: Prevalent PMS Symptoms
Symptom
Reported by (%)
Mood swings
85%
Breast tenderness
75%
Nausea or bloating
60%
Irritability/anxiety
70%
Food cravings
50%
Sleep disturbances
55%
JOURNAL OF NEW CENTURY INNOVATIONS
Volume–76_Issue-1_May-2025
564
564
564
564
Histologically, PMS is associated with the following key changes:
Neuroendocrine activity: Estrogen and progesterone modulate the release of
neurotransmitters such as serotonin and GABA. Decreased serotonin levels in the
midbrain correlate with increased mood lability.
Tissue response: Endometrial tissue undergoes changes due to progesterone
withdrawal, resulting in increased prostaglandin production, which can lead to nausea
and cramps.
Immune activation: Elevated cytokine levels and immune cell activity are
observed in both the uterus and brain, contributing to fatigue and behavioral shifts.
Discussion
The connection between fluctuating sex hormones and observable symptoms in
PMS lies in the tissue-level impact on the central nervous system and reproductive
organs. Progesterone, which increases in the luteal phase and then drops sharply before
menstruation, has an inhibitory effect on neuronal excitability. This decline can lead to
irritability and emotional instability due to reduced GABA activity.
Moreover, serotonin production is closely tied to estrogen levels. When estrogen
decreases, serotonin synthesis and receptor sensitivity are reduced, explaining the
mood-related symptoms. Histological studies reveal altered glial cell activity and
neurotransmitter receptor expression in the hypothalamus during this phase.
In the endometrial lining, progesterone withdrawal leads to increased
prostaglandin secretion, which is associated with inflammation, pain, and
gastrointestinal symptoms such as nausea and bloating. These mechanisms reflect how
cyclical hormonal changes translate into physical discomfort and behavioral changes.
Despite being seen as a normal part of life, PMS involves significant histological
and biochemical changes. Raising awareness of this biology helps validate the
experiences of affected individuals and encourages a more supportive approach in
clinical practice.
JOURNAL OF NEW CENTURY INNOVATIONS
Volume–76_Issue-1_May-2025
565
565
565
565
Conclusion
PMS is not merely a hormonal shift but a complex interplay of neuroendocrine
signals and histological changes. Recognizing its biological roots enables a better
understanding of the condition, promoting empathy and targeted treatment strategies.
Further research and public education are essential to dispel misconceptions and
provide effective care for those affected.
References
1. Rapkin, A.J., & Winer, S.A. (2009). Premenstrual syndrome and premenstrual
dysphoric disorder: Quality of life and burden of illness. Expert Review of
Pharmacoeconomics & Outcomes Research, 9(2), 157–170.
2. Halbreich, U. (2003). The etiology, biology, and evolving pathology of
premenstrual syndromes. Psychoneuroendocrinology, 28, 55–99.
3. Yonkers, K.A. et al. (2008). The role of serotonin in premenstrual syndrome.
CNS Drugs, 22(6), 477–492.
4. Smith, M.J., & Rubinow, D.R. (2018). Endocrine and immune regulation of
mood during the menstrual cycle. Journal of Neuroendocrinology, 30(7).
5. Freeman, E.W. (2003). Premenstrual syndrome and premenstrual dysphoric
disorder: Definitions and diagnosis. Psychoneuroendocrinology, 28, 25–37.
